Gu Xiaoya, Yu Xiaobing, Song Shuang, Dai Hong
Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Beijing, China.
Ophthalmic Res. 2017;58(1):8-14. doi: 10.1159/000458534. Epub 2017 Mar 24.
The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO).
Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection.
BCVA in both groups at each follow-up were significantly increased compared to baseline with no statistical difference between the groups. Ozurdex and ranibizumab successfully reduced CMT at each follow-up. Both CRVO and BRVO patients had significant between-group differences in the mean number of injections. Among the CRVO patients, IOP in the Ozurdex group was significantly increased compared to baseline and the ranibizumab group at 1, 2, and 3 months postinjection.
Intravitreal injection of Ozurdex and ranibizumab can effectively control ME secondary to RVO and increase a patient's BCVA. The advantages of Ozurdex are fewer injections and longer efficacy, while the advantages of ranibizumab include fewer side effects.
本研究旨在比较玻璃体内注射地塞米松植入剂（Ozurdex）和玻璃体内注射雷珠单抗（Lucentis）治疗视网膜静脉阻塞（RVO）所致黄斑水肿（ME）的疗效。
纳入32例接受Ozurdex治疗的ME患者和32例接受雷珠单抗治疗的ME患者，每组各有26例中心性（C）RVO患者和6例分支性（B）RVO患者。我们比较了注射后1、2、3和6个月时的最佳矫正视力（BCVA）、视网膜中央厚度、注射次数和眼压（IOP）结果。
与基线相比，两组在每次随访时的BCVA均显著提高，组间无统计学差异。Ozurdex和雷珠单抗在每次随访时均成功降低了中心凹视网膜厚度（CMT）。CRVO和BRVO患者在平均注射次数上均存在显著组间差异。在CRVO患者中，Ozurdex组在注射后1、2和3个月时的眼压与基线相比显著升高，且高于雷珠单抗组。
玻璃体内注射Ozurdex和雷珠单抗可有效控制RVO继发的ME并提高患者的BCVA。Ozurdex的优点是注射次数少、疗效持续时间长，而雷珠单抗的优点是副作用少。
